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 West Nile Virus 
Lineage 2 from 
Blood Donor, 
Greece
To the Editor: West Nile virus 
(WNV) is a mosquito-borne fl avivirus 
that primarily causes an asymptomatic 
or mild disease in humans; however, 
in <1% of infected persons, it causes 
neurologic disease. The virus has 
received increased attention since 
2002 when it was established that 
WNV is transmissible by blood 
transfusion and organ transplantation 
(1).
A major WNV outbreak occurred 
in 2010 in Greece; most cases occurred 
in the northern part of the country 
(2). Of the 197 WNV neuroinvasive 
cases reported, 33 were fatal (3). 
Many nonneuroinvasive cases were 
observed (4). A lineage 2 WNV 
(Nea Santa-Greece-2010 strain) was 
detected in Culex pipiens mosquitoes 
collected at 2 locations where WNV 
cases had been reported (5). Although 
this strain shows  high genetic identity 
to a Hungarian WNV strain isolated 
from birds in 2004, it has the amino 
acid substitution H249P in nonstructural 
protein 3 (NS3) (6). This mutation 
has been associated with increased 
virulence in WNV lineage 1 strains 
(7). Clinical WNV disease in humans 
had not been previously documented 
in Greece, and surveillance of blood 
donors in 2006 and 2007 did not show 
any WNV-positive result (8).
On August 11, 2010, shortly after 
confi rmation of the outbreak of WNV 
infections in humans in Greece, an 
action plan for the protection of blood 
safety was initiated. All donors were 
asked to report any fever-like illness 
up to 15 days after donation. Individual 
donation nucleic acid testing (NAT) of 
all blood donors living in the WNV-
affected areas was implemented on 
August 22, 2010.
The fi rst WNV-positive by NAT 
result was obtained from a sample 
donated on August 22. Testing was 
performed by using the automated 
Procleix TIGRIS System (Chiron 
Corporation, Emeryville, CA, USA). 
The WNV-positive blood donor was 
a 40-year-old immunocompetent 
woman, a resident of a village in 
northern Greece. The village is located 
between 2 lakes, and the area is one 
of Europe’s major wetlands. The 2 
locations where the WNV-positive 
mosquitoes were collected are near 
each other (online Appendix Figure, 
wwwnc.cdc.gov/EID/article/18/4/11-
0771-FA1.htm). The woman was 
working in an open-air fi sh market and 
reported numerous mosquito bites. At 
the time of blood donation, she was 
asymptomatic; 2 days later she had 
myalgia, arthralgia, and severe retro-
orbital pain, lasting 2–3 days each. A 
second blood sample taken on August 
26 was also NAT positive.
Serologic testing for WNV IgM 
and IgG was performed by ELISA 
(WNV IgM Capture DxSelect 
and WNV IgG DxSelect; Focus 
Diagnostics Inc., Cypress, CA, USA). 
An index ≈1.5 for IgM and ≈1.1 for 
IgG was considered positive. No 
antibodies were detected in the initial 
and second serum samples; however, 
a third sample taken on September 20 
was positive for WNV IgM and IgG 
(indices 4.7 and 3.8, respectively).
Nested reverse transcription 
PCRs with the initial blood sample 
gave positive results (9,10). WNV 
lineage 2 sequences were obtained 
and were identical to those of the 
Nea Santa-Greece-2010 strain (6). 
One milliliter of each 1:10 and 1:100 
dilution of whole blood in minimum 
essential medium containing 
antimicrobial drugs and 2% fetal 
bovine serum was placed on Vero E6 
cell monolayers in 25-cm2 cell culture 
fl asks. The procedure was performed 
in a biosafety level 3 laboratory, in 
which WNV lineage 2 had never 
been handled. After the sample was 
incubated 1 hour at 37°C in a 5% 
CO2 incubator, 9 mL of fresh medium 
containing 4% fetal bovine serum was 
added.
Cytopathic effects were observed 
in the fl ask inoculated with the 1:100 
dilution on day 3 after infection. 
An aliquot of supernatant was used 
to infect fresh cell monolayers. 
WNV growth in the cell culture was 
demonstrated by reverse transcription 
PCR and immunofl uorescence assay. 
Sequences of the cell culture isolate 
were identical to those of the directly 
detected virus. 
To check whether the isolate 
possessed the H249P substitution, a 
set of nested primers spanning the 
region 5140–5660 from the WNV 
genome was designed: NS3a-5′-
GCTGGCTTCGAACCTGA-3′and 
NS3b-5′-CAATCATCGTTCTTGC-3′ 
for the fi rst round PCR and NS3c-5′-
GCTGCTGAGATGTCTGA-3′and 
N S 3 d - 5 ′ - T C ATAT C C A G T G T T
CCA-3′ for the nested PCR. The H249P 
substitution was present. Sequences 
were submitted to GenBank (accession 
nos. JF917091, JF917092).
Virus isolation from WNV patients 
is usually unsuccessful because 
viremia levels are low and last only 
a short time. WNV strains are usually 
isolated from immunocompromised 
patients, blood donors, IgM-negative 
immunocompetent patients who 
seroconverted, or autopsy brain 
samples. For the donor reported here, 
WNV was isolated 2 days before 
illness onset, when no antibodies were 
present. The WNV-positive blood 
donor was detected 1 day after the 
introduction of blood screening.
The early diagnosis of the initial 
human WNV cases in Greece, which 
resulted in prompt implementation of 
NAT testing, had a substantial positive 
impact on the safety of the blood 
supply in the affected areas. The risk 
for virus transmission was reduced for 
blood recipients, in particular those 
who receive multiple transfusions and 
immunocompromised patients in need 
of transfusion.
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To the Editor: Prisons represent 
a crucial setting for tuberculosis (TB) 
control. Worldwide, reported TB rates 
for correctional system populations 
have been 10–100× higher than rates 
for the local civilian populations, and 
TB outbreaks with a high number of 
TB multidrug-resistant cases have 
been documented (1,2). Prisons 
are known as social and sanitary 
pathology reservoirs in which TB 
is often associated with chronic 
infectious diseases caused by HIV, 
hepatitis B virus (HBV), or hepatitis C 
virus (HCV) (2).
HCV prevalence among inmates 
is 30%–40% (range 2%–58%), which 
is higher than that in the general 
population and is related to injection 
drug use (3). For these reasons, 
effective anti-HCV therapeutic 
approaches are recommended by 
national and international guidelines 
for decreasing illness, death rates, and 
reservoirs of infection in prisons (4,5).
The standard of care for 
patients with chronic hepatitis C 
infection is represented by pegylated 
interferon-α (Peg-IFN) and ribavirin. 
These drugs determine complex 
antiviral, immunomodulatory, and 
antiproliferative actions, which can 
cause serious side effects such as 
leukopenia/neutropenia and alterations 
in the cytokine network (3). Although 
severe cellular immunodefi ciency can 
often facilitate the development of 
many infections, only 4 clinical cases 
of TB in patients undergoing HCV 
antiviral therapy have been described 
in the literature (6–8), and only 1 of 
these was clearly described as a TB 
reactivation (7).
We describe a case of pulmonary 
TB reactivation during therapy with 
Peg-IFN and ribavirin in a 44-year-
old white male inmate, affected by 
genotype 1b/4a chronic hepatitis 
C. After prison admission in 2009, 
he underwent routine screening 
tests for infectious diseases, which 
indicated HCV antibody, HBV surface 
antibody, HBV core IgG antibody, and 
tuberculin skin test positivity. Results 
of chest radiograph and HIV screening 
were negative.
His previous history involved 
injection drug use, smoking, 
and alcohol consumption. Anti-
HCV therapy of directly observed 
administration of Peg-INF 
α-2a (180 μg/wk) and ribavirin 
(1,200 mg/d) was started. During 
therapy, the patient had only mild 
musculoskeletal pain and temporary 
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